UCART-22 is under clinical development by Cellectis and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase II drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how UCART-22’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
UCART-22 overview
UCART-22 is under development for the treatment of relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma (B-NHL). The drug candidate is an allogeneic gene-edited T-cell product candidate. It is an immunotherapy comprising of CAR T cells and acts by targeting CD22. It was also under development for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). It is administered through intravenous route.
Cellectis overview
Cellectis, operates as a clinical-stage biopharmaceutical company. It carries out research, develop and commercialize gene editing technology. The company’s pipeline products include UCART22, UCART123, UCART20x22, ALLO-501A 1, ALLO-715 3, ALLO-605 3, ALLO-316 4. z Its pipeline candidates treat Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Large B-cell Lymphoma, Multiple Myeloma, Multiple Myeloma, Renal Cell Carcinoma. Cellectis’s pioneer, deploying core proprietary technologies to develop off-the-shelf immunotherapies to target and eradicate cancer cells. It works in partnership with Allogene Therapeutics, Servier, Iovance Biotherapeutics, Inc, Cytovia Therapeutics, Inc., It operates in New York and Paris. Cellectis is headquartered in Paris, France.
For a complete picture of UCART-22’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
